VORICONAZOLE-GX voriconazole 50mg tablet blister pack

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

voriconazole, Quantity: 50 mg

Disponible depuis:

Medis Pharma Pty Ltd

DCI (Dénomination commune internationale):

Voriconazole

forme pharmaceutique:

Tablet, film coated

Composition:

Excipient Ingredients: microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; magnesium stearate; povidone; titanium dioxide; hypromellose; triacetin; macrogol 3350

Mode d'administration:

Oral

Unités en paquet:

2, 56, 10, 14, 28, 20, 30, 100, 50

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

VORICONAZOLE-GX is indicated for treatment of the following fungal infections:,Invasive aspergillosis.,Serious Candida infections (including C. krusei), including oesophageal and systemic Candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,Serious fungal infections caused by Scedosporium spp and Fusarium spp.,Other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,Prophylaxis in patients who are at high risk of developing invasive fungal infections. The indication is based on studies including patients undergoing haematopoietic stem cell transplantation. This brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets.

Descriptif du produit:

Visual Identification: white, round biconvex tablets, debossed 'VC50' on one side and plain on the reverse'; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius

Statut de autorisation:

Licence status A

Date de l'autorisation:

2015-02-02